

Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030

<https://marketpublishers.com/r/GD6AB7BE848DEN.html>

Date: April 2025

Pages: 240

Price: US\$ 2,400.00 (Single User License)

ID: GD6AB7BE848DEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030
Report Findings & Highlights:

Research Methodology

Global & Regional Market Trends Insight

First KRAS Inhibitor Drug Approved In 2021

Global KRAS Market Opportunity To Surpass US\$ 2 Billion By 2030

KRAS Inhibitors Market Absolute Growth: >400% Since First Drug Approval

Approved KRAS Inhibitors Drugs: 4 Drugs

Approved Drugs Dosage, Price & Sales Insight

Insight On More Than 80 Drugs In Clinical Trials

KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication & Phase

The global market for KRAS inhibitors has seen substantial growth in recent years, largely due to the heightened awareness of KRAS mutations as significant contributors

to cancer development in various solid tumors, including lung, colorectal, and pancreatic cancers. KRAS, an essential gene that regulates cell proliferation, has historically posed a challenge as a therapeutic target because of its intricate biology and its function in supporting tumor survival. Nevertheless, advancements in molecular biology and the creation of targeted therapies have led to the emergence of KRAS inhibitors as a promising category of medications.

A pivotal moment in the KRAS inhibitor market occurred in 2021 with the approval of Lumakras for the treatment of non-small cell lung cancer (NSCLC), representing a significant breakthrough for patients with KRAS G12C mutations. This approval heralded a new phase in targeted cancer therapies, followed by the authorization of Krazati in 2022, and Dupert and Anfangning in 2024 for NSCLC, thereby broadening the treatment landscape for patients with this particular genetic alteration. In 2024 and 2025, the market continued to expand, with both Krazati and Lumakras receiving additional approvals for colorectal cancer (CRC).

At present, more than 80 KRAS inhibitors are in various stages of clinical trials, including Roche's Divarasib, which is currently in Phase 3 trials, and Jacobio Pharma's Glecirasib (JAB-21822), which is undergoing registrational trials in China. The ongoing development of these agents highlights the extensive potential of KRAS inhibitors in addressing a range of malignancies, with numerous clinical trials exploring their use in combination with other cancer treatments, such as chemotherapy, immunotherapy, and targeted therapies. The approval and growing utilization of KRAS inhibitors emphasize their importance in oncology, especially for cancers that have few treatment alternatives and poor outcomes.

Lung cancer, especially non-small cell lung cancer (NSCLC), continues to be the primary focus of research on KRAS inhibitors, with many clinical trials investigating KRAS G12C mutations. Nonetheless, colorectal and pancreatic cancers are also critical areas of study, as KRAS mutations are commonly observed in these types of cancer. The therapeutic potential of KRAS inhibitors extends beyond these malignancies, with ongoing investigations into their effectiveness against other cancers, such as ovarian, brain, and endometrial cancers. Consequently, the global market for KRAS inhibitors is anticipated to broaden, encompassing a wider variety of cancer types, fueled by increasing clinical evidence that supports the efficacy of these treatments across diverse tumor types.

KRAS inhibitors primarily target specific mutations in the KRAS gene, with G12C, G12V, and G12D being the most prevalent. These mutations play a significant role in the oncogenic activation of KRAS, making it an important target for therapeutic strategies. While traditional KRAS inhibitors have focused on either the active or inactive states of the KRAS protein, the emergence of next-generation inhibitors capable of targeting both the "ON" and "OFF" states of KRAS has created new therapeutic possibilities. An

example of such an inhibitor is BBO-8520 from BridgeBio Oncology Therapeutics, which covalently binds to both the active and inactive forms of KRAS G12C, effectively preventing effector binding and inhibiting KRAS function. Preclinical studies indicate that BBO-8520 demonstrates greater potency, more profound tumor responses, and a delay in resistance compared to standard KRAS G12C inhibitors, positioning it as a promising option to address the limitations of existing therapies.

Looking ahead, the global market for KRAS inhibitors is set for significant growth as an increasing number of inhibitors advance through clinical trials and receive regulatory approval. Ongoing investigations into combination therapies are expected to broaden the range of treatment options available, targeting various KRAS mutation subtypes and extending to other cancers beyond non-small cell lung cancer (NSCLC). Furthermore, the emergence of more international partnerships and collaborations will likely enhance global access to these vital treatments, thereby benefiting a larger segment of cancer patients. Nevertheless, challenges such as high treatment costs, issues related to accessibility, and the necessity for continued research into long-term efficacy and safety must be addressed to ensure the market's sustainable development.

Contents

1. INTRODUCTION TO KRAS INHIBITORS

1.1 Development Of KRAS Inhibitors

1.2 Mechanism Of Action

2. ROLE OF KRAS INHIBITORS IN CANCER THERAPY

3. GLOBAL KRAS INHIBITOR MARKET OUTLOOK

3.1 Current Market Scenario

3.2 KRAS Inhibitors Granted Breakthrough Therapy, Fast Track & Orphan Designation

3.3 Future Market Opportunity

4. LUMAKRAS - OVERVIEW, PRICING, DOSING & SALES ANALYSIS

4.1 Overview & Patent Insight

4.2 Dosage & Price Analysis

4.3 Sales Analysis

5. KRAZATI - OVERVIEW, PRICING, DOSING & SALES ANALYSIS

5.1 Overview & Patent Insight

5.2 Dosage & Price Analysis

5.3 Sales Analysis

6. DUPERT - CLINICAL INSIGHT

7. ANFANGNING - CLINICAL INSIGHT

8. KRAS INHIBITOR MARKET REGIONAL ANALYSIS - COMMERCIAL & CLINICAL DEVELOPMENT OUTLOOK

8.1 US

8.2 China

8.3 EU

8.4 UK

- 8.5 Japan
- 8.6 South Korea
- 8.7 Canada
- 8.8 Taiwan
- 8.9 Australia

9. KRAS INHIBITOR DEVELOPMENT TRENDS BY INDICATIONS

- 9.1 Lung Cancer
- 9.2 Colorectal Cancer
- 9.3 Pancreatic Cancer
- 9.4 Other Indications

10. GLOBAL KRAS INHIBITORS CLINICAL PIPELINE OVERVIEW

- 10.1 By Country
- 10.2 By Phase
- 10.3 By Company
- 10.4 By Indication
- 10.5 By Priority Status

11. GLOBAL KRAS INHIBITOR CLINICAL TRIALS INSIGHT BY COUNTRY, COMPANY, INDICATION & PHASE

- 11.1 Research
- 11.2 Preclinical
- 11.3 Phase I
- 11.4 Phase I/II
- 11.5 Phase II
- 11.6 Phase III
- 11.7 Preregistration
- 11.8 Registered

12. MARKETED KRAS INHIBITOR CLINICAL TRIALS INSIGHT

13. KRAS INHIBITORS COMBINATION STRATEGIES

- 13.1 Immunotherapy
- 13.2 Chemotherapy

13.3 Targeted Therapies

13.4 Radiation

14. GLOBAL KRAS INHIBITORS MARKET DYNAMICS

14.1 Market Drivers

14.2 Market Challenges

15. COMPETITIVE LANDSCAPE

15.1 Applied Pharmaceutical Science

15.2 Amgen

15.3 AnBogen Therapeutics

15.4 AstraZeneca

15.5 Biond Biologics

15.6 BridgeBio Oncology Therapeutics

15.7 Bristol Myers Squibb

15.8 Boehringer Ingelheim

15.9 Eli Lilly

15.10 Erasca

15.11 Frontier Medicines

15.12 GenFleet Therapeutics

15.13 Innovent Bio

15.14 Jacobio Pharmaceuticals

15.15 Jiangsu Hansoh Pharmaceutical

15.16 Jiangsu Hengrui Medicine Co.

15.17 Quanta Therapeutics

15.18 Revolution Medicines

15.19 Roche

15.20 Suzhou Zelgen Biopharmaceuticals

Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS & NRAS Mutations

Figure 1-2: KRAS Inhibitors – Development Milestones

Figure 1-3: KRAS Inhibitor - General Mechanism In Cancer

Figure 1-4: KRAS Inhibitors - Targeting Approaches

Figure 1-5: Direct Targeting of Mutant KRAS

Figure 1-6: Targets for Modifying the KRAS Membrane Association

Figure 2-1: KRAS Mutational Frequency By Organ (%)

Figure 2-2: KRAS Inhibitor – Role In Cancer Treatment

Figure 3-1: Approved KRAS Inhibitors

- Figure 3-2: Global - KRAS Inhibitors Sales (US\$ Million), 2021-2024
- Figure 3-3: Global - KRAS Inhibitors Quarterly Sales (US\$ Million), Q1-Q4'2024
- Figure 3-4: KRAS Inhibitor Market - Future Opportunities
- Figure 3-5: Global - KRAS Inhibitors Sales (US\$ Million), 2025-2030
- Figure 4-1: Sotorasib - Approval Year By Indication
- Figure 4-2: Sotorasib - Patent Expiration Year
- Figure 4-3: US - Cost Per Unit & Supply Of Lumakras (US\$), April'2025
- Figure 4-4: EU - Cost Per Unit & Supply Of Lumakras (US\$), April'2025
- Figure 4-5: Lumakras - Recommended Dose Reduction Levels For Adverse Reaction
- Figure 4-6: Global - Lumakras/Lumykras Annual Sales (US\$ Million), 2021-2024
- Figure 4-7: Global - Lumakras/Lumykras Sales (US\$ Million), Q1-Q4'2024
- Figure 4-8: Regional - US v/s ROW Lumakras/Lumykras Sales (US\$ Million), 2024
- Figure 4-9: Regional - US v/s ROW Lumakras/Lumykras Sales (%), 2024
- Figure 4-10: US - Lumakras Sales (US\$ Million), 2021-2024
- Figure 4-11: US - Lumakras Sales (US\$ Million), Q1-Q4'2024
- Figure 4-12: ROW – Lumakras/Lumykras Sales (US\$ Million), 2021-2024
- Figure 4-13: ROW – Lumakras/Lumykras Sales (US\$ Million), Q1-Q4'2024
- Figure 5-1: Krazati - Approval Year By Indication
- Figure 5-2: Krazati - Market Exclusivity Expiry By Region
- Figure 5-3: US - Cost Per Unit & Supply Of Krazati (US\$), April'2025
- Figure 5-4: Krazati - Recommended Dosage Reduction for Adverse Reactions (mg/day)
- Figure 5-5: Global - Krazati Annual Sales (US\$ Million), 2023-2024
- Figure 5-6: Global - Krazati Quarterly Sales (US\$ Million), Q1-Q4'2024
- Figure 5-7: Regional - US v/s ROW Krazati Sales (US\$ Million), 2024
- Figure 5-8: Regional - US v/s ROW Krazati Sales (%), 2024
- Figure 5-9: US - Krazati Sales (US\$ Million), Q1-Q4'2024
- Figure 5-10: ROW - Krazati Sales (US\$ Million), Q1-Q4'2024
- Figure 7-1: Garsorasib - NMPA Breakthrough Therapy Designation Year By Indication
- Figure 9-1: TBBO8520-101 Phase 1 Study (NCT06343402) – Initiation & Completion Year
- Figure 9-2: KRYSTAL-12 Phase 3 Study (NCT04685135) – Initiation & Completion Year
- Figure 9-3: RAMP203/VS-6766-203 Phase 1/2 Study (NCT05074810) – Initiation & Completion Year
- Figure 9-4: RASolve 301 Phase 3 (NCT06881784) Study – Initiation & Completion Year
- Figure 9-5: RMC-LUNG-101 Phase 1/2 (NCT06162221) Study – Initiation & Completion Year
- Figure 9-6: CodeBreak 301 Phase 3 (NCT06252649) Study – Initiation & Completion Year
- Figure 9-7: CodeBreak 101 Phase 3 (NCT04185883) Study – Initiation & Completion Year

Year

Figure 9-8: KRYSTAL-10 Phase 3 (NCT04793958) Study – Initiation & Completion Year

Figure 9-9: RMC-6291-101 Phase 1 (NCT06128551) Study – Initiation & Completion Year

Figure 9-10: RMC-6236-001 Phase 1 (NCT05379985) Study – Initiation & Completion Year

Figure 9-11: RMC-9805-001 Phase 1 (NCT06040541) Study – Initiation & Completion Year

Figure 9-12: BrainMet ADePPT Phase 1 (NCT06807619) Study – Initiation & Completion Year

Figure 9-13: NCI-2023-09685 Phase 1 (NCT06130254) Study – Initiation & Completion Year

Figure 10-1: Global - KRAS Protein Inhibitors Clinical Trials By Country, 2025 -2030

Figure 10-2: Global - KRAS Protein Inhibitors Clinical Trials By Phase, 2025 -2030

Figure 10-3: Global - KRAS Protein Inhibitors Clinical Trials By Company, 2025 -2030

Figure 10-4: Global - KRAS Protein Inhibitors Clinical Trials By Indication, 2025 -2030

Figure 10-5: Global - KRAS Protein Inhibitors Clinical Trials By Priority Status, 2025 -2030

Figure 13-1: KRAS inhibitors & Immunotherapy Combinations

Figure 14-1: KRAS Inhibitors Market - Drivers

Figure 14-2: KRAS Inhibitors Market - Challenges

Table 3-1: KRAS Inhibitors Breakthrough Therapy, Fast Track & Orphan Designation

Table 4-1: Lumakras - Recommended Dosage Modifications For Adverse Reactions

Table 5-1: Krazati - Recommended Dosage Modifications For Adverse Reactions

Table 8-1: US - Ongoing KRAS Inhibitor Clinical Trials

Table 8-2: China - Ongoing KRAS Inhibitor Clinical Trials

Table 8-3: UK - Ongoing KRAS Inhibitor Clinical Trials

Table 8-4: Japan - Ongoing KRAS Inhibitor Clinical Trials

Table 8-5: South Korea - Ongoing KRAS Inhibitor Clinical Trials

Table 8-6: Canada - Ongoing KRAS Inhibitor Clinical Trials

Table 8-7: Taiwan - Ongoing KRAS Inhibitor Clinical Trials

Table 8-8: Australia - Ongoing KRAS Inhibitor Clinical Trials

Table 9-1: Lung Cancer - KRAS Inhibitors In Clinical Trials

Table 9-2: Colorectal Cancer - KRAS Inhibitors In Clinical Trials

Table 9-3: Colorectal Cancer - KRAS Inhibitors With Regulatory Designations

Table 9-4: Pancreatic Cancer - KRAS Inhibitors in Clinical Trials

Table 9-5: Pancreatic Cancer - KRAS Inhibitors with Regulatory Designations

Table 13-1: KRAS Inhibitor & Immunotherapy Combinations In Clinical Trials

Table 13-2: KRAS Inhibitor & Chemotherapy Combinations In Clinical Trials

Table 13-3: KRAS Inhibitor & Targeted Therapy Combinations In Clinical Trials

Table 13-4: KRAS Inhibitor & Radiotherapy Combinations In Clinical Trials

I would like to order

Product name: Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030

Product link: <https://marketpublishers.com/r/GD6AB7BE848DEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD6AB7BE848DEN.html>